2024
Coherent Biopharma (Hefei) Co., Ltd established
CBP-1019 launched expansion clinical trial both in China and the U.S.
2023
Qijing Biopharma (Shanghai) Co., Ltd established
Coherent Biopharma (Wenzhou) Co., Ltd established
CBP-1008 launched pivotal Ph lI clinical trial
CBP-1018 launched expansion clinical trial
CBP-1019 launched Ph la clinical trial both in China and the U.S.
2022
Completed series B & B+ financing
CBP-1019 IND declared both in China and the U.S.
CBP-1008 completed Ph lb OC clinical trial
CBP-1018 completed Ph la clinical trial
2021
Coherent Biopharma (Beijing) Co., Ltd established
CBP-1018 approved by FDA for clinical study
CBP-1008 completed Ph la clinical trial and launched Ph lb clinical trial
CBP-1018 launched Ph I/II clinical trial
2020
Coherent Biopharma LLC (U.S.) established
Coherent Biopharma Pty Ltd (Australia) established
Coherent Biopharma l, Limited (Hong Kong) established
CBP-1008 approved by FDA for clinical study
CBP-1008 approved by FDA for clinical study
2019
Invested $5M to build a new R & D center covering an area of 3,600 square
2017
CBP-1008 approved by NMPA for clinical study
2016
Coherent Biopharma (Suzhou) Co., Ltd established
2015
Coherent Biopharma (Cayman) established
Coherent Biopharma Limited (Hong Kong) established